Gano Kyle 4

What Happened
Kyle Gano, CEO of Neurocrine Biosciences (NBIX), had a tranche of restricted stock units (RSUs convert/settle) on January 31, 2026. The filing shows conversion/settlement of 2,927 RSUs (reported as derivative exercise/conversion). To satisfy tax withholding on the vesting, 1,580 shares were withheld at a per-share value of $136.06 (total reported value withheld $214,975). Net shares delivered to Gano were approximately 1,347 (2,927 converted minus 1,580 withheld). This was a vesting/settlement and tax-withholding event, not an open-market sale or purchase.

Key Details

• Transaction date: January 31, 2026. Filing date: February 3, 2026.
• Conversion/settlement: 2,927 RSUs converted to common shares (reported as code M). Withholding/disposition: 1,580 shares withheld (code F) at $136.06/share = $214,975.
• Net shares delivered to insider: ~1,347 shares (2,927 − 1,580).
• Footnotes: F1 — shares were withheld by the company to satisfy tax withholding; F2 — each RSU equals one share on settlement; F3 — the RSU award was granted Jan 31, 2022 and vested in annual tranches (2023–2026).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No late-filing flag was noted in the provided data.

Context
This was a routine RSU vesting and tax-withholding transaction (not a market sale). Withholding of shares to cover taxes is common and should not be read as a directional buy/sell signal. For investors, outright purchases by insiders tend to carry more informational weight; this filing documents compensation vesting and tax settlement.